{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:44:26Z","timestamp":1793324666433,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.05.013","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T15:45:59Z","timestamp":1749224759000},"page":"594.e9-594.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sex-based differences in genetic alterations and immune checkpoint inhibitor response in urothelial bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6542-9110","authenticated-orcid":false,"given":"Jean-Pierre (Trey)","family":"Kanumuambidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynier Rodriguez","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Toubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Sceats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bandyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2839","authenticated-orcid":false,"given":"K.C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.05.013_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41389-023-00489-9","article-title":"Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions","volume":"12","author":"Doshi","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/BLC-211658","article-title":"Mechanism of sex differences in bladder cancer: evident and elusive sex-biasing factors","volume":"8","author":"Lam","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2018.03.001","article-title":"Bladder cancer survival: women better off in the long run","volume":"95","author":"Andreassen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0004","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.28416","article-title":"Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation","volume":"120","author":"Cohn","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0006","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-18-0362","article-title":"Sex differences in cancer driver genes and biomarkers","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0007","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3390\/ijms21176072","article-title":"Mutational landscape and environmental effects in bladder cancer","volume":"21","author":"Hayashi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv221","article-title":"Gender disparity and mutation burden in metastatic melanoma","volume":"107","author":"Gupta","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0009","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0010","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1002\/tox.24409","article-title":"RB1 Mutations induce smoking-related bladder cancer by modulating the cytochrome P450 pathway","volume":"39","author":"Mao","year":"2024","journal-title":"Environ Toxicol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.15585\/mmwr.mm6702a1","article-title":"Current cigarette smoking among adults \u2014 United States, 2016","volume":"67","author":"Jamal","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12013-015-0574-z","article-title":"Bladder cancer and genetic mutations","volume":"73","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/0014-2964(72)90137-5","article-title":"Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response","volume":"8","author":"Bertram","year":"1972","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0014","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.juro.2018.04.082","article-title":"Bladder cancer survival of men receiving 5\u03b1-reductase inhibitors","volume":"200","author":"M\u00e4kel\u00e4","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00256185","article-title":"Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine","volume":"3","author":"Okajima","year":"1975","journal-title":"Urol Res"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0016","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/biom11040594","article-title":"The role of androgens and androgen receptor in Human bladder cancer","volume":"11","author":"Mart\u00ednez-Rojo","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0017","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nature24265","article-title":"Landscape of X chromosome inactivation across human tissues","volume":"550","author":"Tukiainen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0018","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/oncolo\/oyac180","article-title":"Comprehensive landscape of cyclin pathway gene alterations and Co-occurrence with FGF\/FGFR aberrations across urinary tract tumors","volume":"28","author":"Jardim","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0019","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/BLC-200368","article-title":"Significance and mechanisms analyses of RB1 mutation in bladder cancer disease progression and drug selection by bioinformatics analysis","volume":"7","author":"Zhang","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0020","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and Co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0021","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","article-title":"Invasive bladder cancer: genomic insights and therapeutic promise","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0022","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 Helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192402","article-title":"Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer","volume":"15","author":"Parent","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08078-y","article-title":"RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer","volume":"21","author":"Manzano","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1535-7163.MCT-12-0900","article-title":"Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner","volume":"12","author":"McCarthy","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0026","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","article-title":"A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum","volume":"21","author":"Alekseev","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0027","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/biom11040594","article-title":"The role of androgens and androgen receptor in Human bladder cancer","volume":"11","author":"Mart\u00ednez-Rojo","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106998","article-title":"Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor","volume":"143","author":"Gao","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.640","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): an institutional experience","volume":"38","author":"Schwartzman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-025-07128-z","article-title":"Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study","volume":"18","author":"Kawahara","year":"2025","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0031","doi-asserted-by":"crossref","first-page":"432.e15","DOI":"10.1016\/j.urolonc.2016.05.016","article-title":"Enzalutamide inhibits androgen receptor\u2013positive bladder cancer cell growth","volume":"34","author":"Kawahara","year":"2016","journal-title":"Urolog Oncol"},{"key":"10.1016\/j.urolonc.2025.05.013_bib0032","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers9020020","article-title":"Androgen receptor signaling in bladder cancer","volume":"9","author":"Li","year":"2017","journal-title":"Cancers (Basel)"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:27:59Z","timestamp":1757338079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1078143925002042"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-based differences in genetic alterations and immune checkpoint inhibitor response in urothelial bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}